| dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
| dc.contributor.author | ABAD, ETNA |
| dc.contributor.author | Sandoz, Jeremy |
| dc.contributor.author | Romero Sola, Gerard |
| dc.contributor.author | Zadra, Ivan |
| dc.contributor.author | Urgel-Solas, Julia |
| dc.contributor.author | Borredat, Pablo |
| dc.date.accessioned | 2024-05-22T12:19:55Z |
| dc.date.available | 2024-05-22T12:19:55Z |
| dc.date.issued | 2024-04-29 |
| dc.identifier.citation | Abad E, Sandoz J, Romero G, Zadra I, Urgel-Solas J, Borredat P, et al. The TP53-activated E3 ligase RNF144B is a tumour suppressor that prevents genomic instability. J Exp Clin Cancer Res. 2024 Apr 29;43(1):127. |
| dc.identifier.issn | 1756-9966 |
| dc.identifier.uri | https://hdl.handle.net/11351/11488 |
| dc.description | Aneuploidy; Cancer; Genomic instability |
| dc.description.abstract | Background
TP53, the most frequently mutated gene in human cancers, orchestrates a complex transcriptional program crucial for cancer prevention. While certain TP53-dependent genes have been extensively studied, others, like the recently identified RNF144B, remained poorly understood. This E3 ubiquitin ligase has shown potent tumor suppressor activity in murine Eμ Myc-driven lymphoma, emphasizing its significance in the TP53 network. However, little is known about its targets and its role in cancer development, requiring further exploration. In this work, we investigate RNF144B's impact on tumor suppression beyond the hematopoietic compartment in human cancers.
Methods
Employing TP53 wild-type cells, we generated models lacking RNF144B in both non-transformed and cancerous cells of human and mouse origin. By using proteomics, transcriptomics, and functional analysis, we assessed RNF144B's impact in cellular proliferation and transformation. Through in vitro and in vivo experiments, we explored proliferation, DNA repair, cell cycle control, mitotic progression, and treatment resistance. Findings were contrasted with clinical datasets and bioinformatics analysis.
Results
Our research underscores RNF144B's pivotal role as a tumor suppressor, particularly in lung adenocarcinoma. In both human and mouse oncogene-expressing cells, RNF144B deficiency heightened cellular proliferation and transformation. Proteomic and transcriptomic analysis revealed RNF144B's novel function in mediating protein degradation associated with cell cycle progression, DNA damage response and genomic stability. RNF144B deficiency induced chromosomal instability, mitotic defects, and correlated with elevated aneuploidy and worse prognosis in human tumors. Furthermore, RNF144B-deficient lung adenocarcinoma cells exhibited resistance to cell cycle inhibitors that induce chromosomal instability.
Conclusions
Supported by clinical data, our study suggests that RNF144B plays a pivotal role in maintaining genomic stability during tumor suppression. |
| dc.language.iso | eng |
| dc.publisher | BioMed Central |
| dc.relation.ispartofseries | Journal of Experimental & Clinical Cancer Research;43(1) |
| dc.rights | Attribution 4.0 International |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
| dc.source | Scientia |
| dc.subject | Anomalies cromosòmiques |
| dc.subject | Pulmons - Càncer - Aspectes genètics |
| dc.subject | Proteïnes supressores de tumors |
| dc.subject.mesh | Adenocarcinoma of Lung |
| dc.subject.mesh | /genetics |
| dc.subject.mesh | Tumor Suppressor Protein p53 |
| dc.subject.mesh | Genomic Instability |
| dc.title | The TP53-activated E3 ligase RNF144B is a tumour suppressor that prevents genomic instability |
| dc.type | info:eu-repo/semantics/article |
| dc.identifier.doi | 10.1186/s13046-024-03045-4 |
| dc.subject.decs | adenocarcinoma de pulmón |
| dc.subject.decs | /genética |
| dc.subject.decs | proteína supresora de tumor p53 |
| dc.subject.decs | inestabilidad genómica |
| dc.relation.publishversion | https://doi.org/10.1186/s13046-024-03045-4 |
| dc.type.version | info:eu-repo/semantics/publishedVersion |
| dc.audience | Professionals |
| dc.contributor.organismes | Institut Català de la Salut |
| dc.contributor.authoraffiliation | [Abad E, Sandoz J, Zadra I, Borredat P] Department of Medicine and Life Sciences, Universidad Pompeu Fabra, Barcelona, Spain. [Romero G] Department of Medicine and Life Sciences, Universidad Pompeu Fabra, Barcelona, Spain. Thoracic Cancers Translational Genomics Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Urgel Solas J] Department of Medicine and Life Sciences, Universidad Pompeu Fabra, Barcelona, Spain. Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain |
| dc.identifier.pmid | 38685100 |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess |